Deep Dive In Vitiligo

A paused drug program. A reasonable suspicion. Then the question under it: why is there still no cure?

In this episode, Yan Valle argues there is no hidden pill in a glass tower. Companies are not charities, and they are not sitting on a cure because a chronic treatment pays better. The harder account is ordinary. Academia funds what it can publish. Biotech bets on the next round. Pharma keeps what can survive the regulators and the market. Insurers pay for this year’s budget. Patients inherit the sum.

A program can die before anyone knows if the biology was right — a bet on another bet, ten years out, before the casino is built. Early treatment of active vitiligo sounds obvious, and still loses to step therapy and a planning horizon shorter than a child’s year. The price on the receipt was not set by one hand. And “they buried the cure” is easier to air than a system with no villain.

Misconduct is real. This is not a defense of it. But systems before conspiracy is usually the better place to start.

The full essay is on the VRF site. Ten minutes. A double coffee is welcome.

Your skin may enter the room first. Your job is to make sure your work takes over the conversation.

Visible vitiligo does not change competence. It can still change interviews, promotions, and how “professional” gets judged — especially when the face is involved. That is a social problem, not a skills problem. Social problems need strategy, boundaries, and sometimes a little documentation.

In this episode we cover the unglamorous playbook: how to build a case instead of a vibe, what to say if someone stares or asks the wrong question, when disclosure helps and when it doesn’t, and which workplace protections may apply in the US and the UK.

Bias exists. So do portfolios, notes, and the right to leave.

Your skin is not the product.

Prefer reading to listening? The companion article expands on the themes in this episode: Career Success with Visible Vitiligo.

Fifteen years ago, keeping up with vitiligo news was easy. There simply wasn’t that much of it.

Today, research, clinical trials, industry updates, patient discussions, and AI-generated answers arrive faster than anyone can realistically process them.

In Episode 78 of Deep Dive in Vitiligo, we look at what happens next: people stop searching, comparing, and opening twenty browser tabs — and start asking AI to do the thinking for them.

That shift has a name: cognitive surrender.

We explore why handing part of the decision-making process to ChatGPT and other AI tools can be perfectly rational, where it becomes risky, and why pharma companies, doctors, and patient organizations suddenly need to care about what AI says when someone asks a very simple question:

“What are my options?”

AI may be both the cause of the information flood and our best tool for navigating it. Just don’t let it out of the fire pit.

📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.

15 Years of Vitiligo News Publication

What changes when vitiligo puts on a uniform?

The disease stays the same. Almost everything around it changes — from medical fitness and deployment to treatment access, military records, VA care, and disability claims.

In this episode of Deep Dive in Vitiligo, we follow the patient journey from sick call to civilian care and examine where people, records, and responsibility can fall through the cracks.

We also separate three questions that are too often mixed together:

We close with a preview of Massé World’s Honor Without Exception, a free symposium bringing service members, veterans, clinicians, researchers, and policymakers together in Miramar, Florida, on November 14, 2026.

Same skin condition. Different rules. Much higher stakes.

📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.

Durante años, la crema aprobada se detenía a los 12. Los más pequeños se quedaban con el menú de siempre: corticoides, tacrolimus, luz si había hueco, y mucha espera.

Eso empieza a cambiar. Hay dos ensayos de fase 3 con crema de ruxolitinib — Opzelura, si ya conoces el tubo — en niños con la forma más común de vitíligo. Protocolos de verdad. Centros de verdad. No un rumor de un grupo de padres.

El matiz: no son el mismo estudio. Si los mezclas, una familia reserva viaje al continente equivocado.

En este episodio de *Deep Dive in Vitiligo* ponemos los dos ensayos uno al lado del otro.

Vas a escuchar:

No suspendas un tratamiento que ya funciona porque en la misma semana aparecieron dos páginas de ensayo. Pregunta en el centro qué habría que pausar. Después llama al dermatólogo habitual del niño.

Sí es una respuesta razonable. No también. La pregunta útil es qué protocolo — si es que alguno — encaja con este niño, en este país, con esta agenda.

For years, approved ruxolitinib cream has stopped at age 12. Younger children have had a much shorter menu: steroids, tacrolimus, light therapy if you can get a slot, and a lot of waiting.

Now two Phase III studies are evaluating ruxolitinib cream in younger children. Its use for vitiligo in these age groups is investigational — researchers are still finding out how well it works and how safe it is. Real protocols. Real sites. Not a rumor from a parent group.

Then the catch: they are not the same study. Mix them up and a family books the wrong continent.

In this episode of Deep Dive in Vitiligo, we put the trials side by side.

You’ll hear:

Do not stop a working routine because two trial pages appeared in the same week. Ask the site what would pause. Then call the child’s regular dermatologist.

Yes is a reasonable answer. No is a reasonable answer. The useful question is which protocol — if either — fits this child, in this country, with this schedule.

Both studies discussed in this episode are sponsored by Incyte Corporation. VRF provides patient education and study-awareness support related to Incyte pediatric vitiligo research under a paid services agreement. VRF does not determine study eligibility or recommend participation.

📚 Prefer reading to listening? These two companion articles expand on many of the themes discussed in this episode.

Most people think gloves are simple: put them on, protect your hands, move on with life.

Unfortunately, your skin didn’t get that memo.

In this episode of Deep Dive in Vitiligo, we explore the surprisingly complicated world of work gloves, hand dermatitis, chemical leukoderma, and the Koebner phenomenon. Why do some gloves trigger itching, cracking, or irritation? Why can friction matter almost as much as chemicals? And why are many dermatologists quietly steering patients toward accelerator-free nitrile gloves?

We compare latex, vinyl, and nitrile options, discuss cotton and silk liners, tackle the rise of biodegradable “eco-friendly” gloves, and explain how a simple choice at the hardware store or workplace can affect long-term hand health.

No fear-mongering. No glove industry conspiracies. Just practical advice to help your hands do their job without becoming part of the problem.

Because the best glove is supposed to protect your skin — not give it a new hobby. 

📚 Prefer reading to listening? The companion article expands on many of the themes discussed in this episode.

Not every vitiligo lesson has to come from a doctor’s office.

In this episode of Deep Dive in Vitiligo, we explore some of the best children’s books about vitiligo—from heartfelt stories of self-acceptance to practical tools that help kids explain their skin to friends, classmates, and even themselves.

We discuss how books can build confidence long before a child learns the medical terminology, and which titles are actually worth adding to your family library.

Whether you’re a parent, grandparent, teacher, healthcare professional, or simply looking for a thoughtful gift, this episode offers a guided tour through the growing world of vitiligo literature for young readers.

Because sometimes a story can do what a prescription cannot. ✨

📚 Prefer reading to listening? The companion article expands on many of the themes discussed in this episode, with links to find these titles online.

Vitamin D matters in vitiligo. Megadoses? That’s where things get interesting — and risky.

In this episode, we unpack the hype around high-dose vitamin D, the Coimbra Protocol, and the small Brazilian study that made patients pay attention.

We cover the possible immune benefits, the real safety concerns — hypercalcemia, kidney stones, strict monitoring — and why correcting a deficiency is not the same as taking massive doses.

Promising biology. Preliminary evidence. Poor safety. No miracle-cure fireworks.

📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.

Patients used to Google their symptoms. Now they ask AI what the hell to do next.

In this episode of Deep Dive in Vitiligo, we unpack “cognitive surrender” — that quiet moment when people stop wrestling the information jungle and just hand the steering wheel to an AI companion.

For pharma, the old playbook is dead. Forget billboards, keywords, and glossy websites. The new arena is whether the AI understands, trusts, and actually recommends your therapy when a patient asks: “What are my real options for this vitiligo?”

Less advertising. More droid advisor.

Welcome to the future of pharmaceutical marketing — where the most important customer might not even be human anymore.

📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.